Compare ClearPoint Neuro Inc (CLPT) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Tidewater Inc — how do they compare? ClearPoint Neuro Inc trades at $15.1 (market cap $462.44M), while Tidewater Inc trades at $90.01 (market cap $4.56B). The key difference: Tidewater Inc is far larger — about 9.9× ClearPoint Neuro Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | TDW | |
|---|---|---|
Market Cap | $462.44M | $4.56B |
Sector | Health | Utilities |
52-Week High | $29.60 | $91.61 |
52-Week Low | $8.66 | $47.29 |
Enterprise Value | $497.03M | $4.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Tidewater (TDW) trades at $91.61, up 2.21% with strong technical momentum and bullish moving average signals. The company reported Q2 2026 earnings of $0.43 per share, beating estimates, with revenue of $342.3 million. Despite recent earnings misses, operational cash flow remains robust at $379 million for 2025, though 2026 projections show declining revenue and margins. Analyst sentiment is mixed with 26.9% buy ratings amid elevated RSI levels suggesting potential overbought conditions.
The stock faces headwinds from declining profitability trends and earnings volatility, but strong institutional ownership and positive technical indicators support near-term upside. Key risks include execution challenges and macroeconomic pressures on the offshore services sector. Investors should weigh solid cash generation against margin compression for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
